A high percentage of stocks that I follow are exhibiting bullish price charts right now. Obviously, you already knew that the stock market has been acting well. I simply want to reiterate that the recent bullishness appears to be sustainable. Enjoy!
Read More
Low-priced stocks offer great year-end profit opportunities. Every year, the vast majority of the low-priced stocks will pop 10% to 20% within a few weeks.
Read More
Stock Recommendation Tracker
The Stock Recommendation Tracker is a table that features all of the current recommendations in all of our portfolios. It’s a quick way for you to see what stocks are currently in our portfolios and will highlight new additions or any to...
Read More
Stock Recommendation Tracker
The Stock Recommendation Tracker is a table that features all of the current recommendations in all of our portfolios. It’s a quick way for you to see what stocks are currently in our portfolios and will highlight new additions or any to...
Read More
From Cabot Top Ten Trader
The market hit a little turbulence early last week on renewed trade worries but bounced back nicely, with the major indexes finishing flat (S&P 500 and Nasdaq) to up (small- and mid-cap) on the week. Short-term, though, we wouldn’t surprised...
Read More
The Big Idea
How psyched would you be if you went to your healthcare provider and they said the following:
“I can make a health optimization recommendation for you, informed not only by the latest clinical trials, but also by local and regional data about like...
Read More
Crista continues to believe this stock is greatly undervalued.
Read More
Profit taking finally set in earlier this week, though this morning’s jobs-inspired pop has erased the losses for the major indexes.
Read More
Three analysts have recently increased their EPS estimates for this e-commerce company.
Read More
A Normal Breather
As the market pushed sharply higher following its early-October low (10% or so in the S&P 500, 12%-plus in the Nasdaq), rising seven out of eight weeks, the worries of the world (trade wars, slowing economic growth, even impeachment) were slowly As...
Read More
This portfolio stock shares are down 7% as investors worry about a potential pharmaceutical competitor.
Read More
Our Emerging Markets Timer as found support in recent weeks, but that hasn’t been enough to produce a new buy signal.
Read More
Our first idea is an oil company that is expected to grow more than 13% this year and has a current annual dividend yield of 5.55%, paid quarterly.
Read More
Not a lot has changed since last week’s issue—overall, the cannabis sector remains in a correction—but there are a few stocks worthy of an update.
Read More
This has been a good year for the market. With only weeks left in 2019, the S&P 500 is more than 23% higher for the year. Some of that is the undoing of the overselling at the end of last year. But the has...
Read More
In the past 30 days, 17 analysts have raised their EPS estimates for this medical device company.
Read More
Short-term, the market remains under pressure, buffeted by the selling of investors scared by the prospects of an extended tariff war, but long-term, the trend remains up, so we still see the current weakness as a normal correction.
Read More
December: Time for a Portfolio Shake-Up
Here we are in December, an interesting time in the stock market, as excessive price movements culminate, often reversing course in January. On the bullish side, you may have owned stocks that rose an abnormal amount, all year We...
Read More
As we wrote a week and a half ago, there’s no Top Ten issue today—one of our two weeks off (50 issues a year). But we don’t want to be too out of touch, which is why we’re sending this brief update today, on...
Read More
*** NEW ADVISORY SERVICE ***
We are pleased to announce that on Tuesday, December 10 we will launch Cabot Profit Booster. This new weekly advisory will feature the experience and skill of two veteran Cabot analysts – Mike Cintolo and Jacob Mintz. Each Tuesday Jacob...
Read More
